These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. US judge dismisses 50m dollars damages in Vioxx lawsuit. Charatan F BMJ; 2006 Sep; 333(7567):516. PubMed ID: 16960199 [No Abstract] [Full Text] [Related]
26. Lessons learned after the withdrawal of rofecoxib. Giaquinta D Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801 [No Abstract] [Full Text] [Related]
27. A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event. Whitstock MT; Pearce CM; Ridout SC; Eckermann EJ Aust N Z J Public Health; 2010 Aug; 34(4):431-2. PubMed ID: 20649787 [No Abstract] [Full Text] [Related]
28. The withdrawal of rofecoxib. Arellano FM Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267 [No Abstract] [Full Text] [Related]
29. Adverse cardiovascular effects of rofecoxib. Nissen SE N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355 [No Abstract] [Full Text] [Related]
30. Adverse cardiovascular effects of rofecoxib. Furberg CD N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442 [No Abstract] [Full Text] [Related]
31. International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. Metcalfe C; Wheeler BW; Gunnell D; Martin RM Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):778-85. PubMed ID: 20680998 [TBL] [Abstract][Full Text] [Related]
32. Selective COX-2 inhibitors: new insights into mechanisms of side effects? Flier S; Buhre W Crit Care Med; 2008 Sep; 36(9):2694-5. PubMed ID: 18728487 [No Abstract] [Full Text] [Related]
33. [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)]. Zeidler H MMW Fortschr Med; 2001 Sep; 143(35-36):14. PubMed ID: 11584521 [No Abstract] [Full Text] [Related]
35. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. Cahana A; Mauron A J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707 [No Abstract] [Full Text] [Related]
36. Medical journal criticizes Merck over Vioxx data. Berenson A N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990 [No Abstract] [Full Text] [Related]
37. Response to expression of concern regarding VIGOR study. Reicin A; Shapiro D N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16544387 [No Abstract] [Full Text] [Related]
38. The Vioxx debacle revisited. Abeles M; Abeles AM Am J Med; 2005 Sep; 118(9):1057-8. PubMed ID: 16164907 [No Abstract] [Full Text] [Related]
39. Seeds of doubt--ADVANTAGE no one. Jackson G Int J Clin Pract; 2008 Nov; 62(11):1637. PubMed ID: 19143848 [No Abstract] [Full Text] [Related]
40. Response to expression of concern regarding VIGOR study. Bombardier C; Laine L; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ; Weaver A N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16495387 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]